These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 17100387)
1. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection. Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. Kiertiburanakul S; Khongnorasat S; Rattanasiri S; Sungkanuparph S J Med Assoc Thai; 2007 Feb; 90(2):237-43. PubMed ID: 17375626 [TBL] [Abstract][Full Text] [Related]
4. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients. Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients. Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042 [TBL] [Abstract][Full Text] [Related]
6. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228 [TBL] [Abstract][Full Text] [Related]
7. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand. Kyaw NL; Thanachartwet V; Kiertiburanakul S; Desakorn V; Chamnanchanunt S; Chierakul W; Manosuthi W; Pitisuttithum P; Sungkanuparph S Southeast Asian J Trop Med Public Health; 2013 Mar; 44(2):232-43. PubMed ID: 23691633 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up. Desakorn V; Karmacharya BM; Thanachartwet V; Kyaw NL; Tansuphaswadikul S; Sahassananda D; Dhitavat J; Maek-a-nantawat W; Pitisuttithum P Southeast Asian J Trop Med Public Health; 2011 Nov; 42(6):1414-22. PubMed ID: 22299411 [TBL] [Abstract][Full Text] [Related]
13. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report. Pensi T Indian Pediatr; 2007 Jul; 44(7):519-21. PubMed ID: 17684304 [TBL] [Abstract][Full Text] [Related]
14. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense. Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857 [TBL] [Abstract][Full Text] [Related]
15. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. Laurent C; Kouanfack C; Koulla-Shiro S; Njoume M; Nkene YM; Ciaffi L; Brulet C; Peytavin G; Vergne L; Calmy A; Mpoudi-Ngolé E; Delaporte E AIDS; 2007 Mar; 21(6):768-71. PubMed ID: 17413701 [TBL] [Abstract][Full Text] [Related]
18. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM; Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874 [TBL] [Abstract][Full Text] [Related]